ENvue Medical to Showcase ENvue™ Navigation Platform at AACN NTI 2026
Rhea-AI Summary
ENvue Medical (NASDAQ: FEED) will exhibit its ENvue™ Navigation Platform at the AACN NTI 2026 conference in Denver on May 21–22, 2026.
The FDA 510(k)-cleared electromagnetic system supports real-time guided bedside feeding tube placement and aligns with hospitals’ focus on workflow efficiency, nursing-led care, and patient safety.
Positive
- None.
Negative
- None.
News Market Reaction – FEED
In the May 19 session, FEED declined 7.92%, reflecting a notable negative market reaction. Argus tracked a peak move of +25.0% during that session. Argus tracked a trough of -12.5% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Contract renewal | Positive | +1.6% | Three-year renewal making ENvue platform standard of care in 12 hospitals. |
| May 08 | IP expansion | Positive | -9.8% | USPTO Notice of Allowance for ultrasound-enhanced cannabinoid delivery technology. |
| May 07 | GPO renewal | Positive | +5.6% | Three-year GPO purchasing renewal covering over 90 hospitals in 17 states. |
| Apr 20 | Customer milestone | Positive | -4.4% | Announcement of 40th U.S. hospital adopting ENvue Navigation Platform. |
| Apr 16 | Corporate update | Positive | -7.5% | Stockholder letter outlining 39 deployed hospitals and 2026 growth priorities. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive operational updates often saw mixed to negative price reactions, with more divergences than alignments between upbeat news and next-day performance.
Over the past months, ENvue Medical reported several commercial milestones and corporate updates. These included a three-year contract renewal across 12 hospitals through 2028, and a three-year GPO purchasing renewal covering over 90 hospitals in 17 states. The company also highlighted reaching its 40th U.S. hospital customer and expanding its IP portfolio with multiple USPTO Notices of Allowance. Despite generally constructive news, price reactions have frequently been muted or negative, similar to today’s response.
Key Terms
enteral access medical
FDA 510(k)-cleared regulatory
bedside feeding tube placement medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company continues expanding commercial presence across critical care markets
TYLER, Texas, May 19, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced that the Company will participate as an exhibitor at the American Association of Critical Care Nurses National Teaching Institute & Critical Care Exposition (“AACN NTI”) 2026, taking place May 21–22, 2026.
Recognized as the largest critical care nursing conference in the United States, AACN NTI brings together thousands of frontline nurses, nurse leaders, educators and healthcare professionals from leading hospitals and healthcare systems nationwide.
“Critical care nurses are central to enteral access and patient management throughout the hospital environment,” said Doron Besser, MD, Chief Executive Officer of ENvue Medical. “We believe that AACN NTI provides an important opportunity for ENvue Medical to engage directly with frontline clinicians, to strengthen clinical awareness of our technology platform, and further expand our commercial presence within critical care settings across the United States.”
At the AACN NTI conference, ENvue Medical will showcase its ENvue™ Navigation Platform, an FDA 510(k)-cleared electromagnetic navigation system designed to support real-time visualization during bedside feeding tube placement procedures.
The Company’s participation at AACN NTI supports its broader commercial growth strategy as hospitals increasingly prioritize bedside workflow efficiency, nursing-led care delivery, patient safety, and reductions in procedural delays associated with traditional feeding tube placement methods.
“We believe that NTI remains one of the most important clinical engagement opportunities of the year for our commercial organization,” said Marc Waldman, Vice President Commercial of ENvue Medical. “We continue to see growing interest from hospitals and clinical teams seeking bedside enteral access solutions that support workflow efficiency, nursing empowerment, and informed clinical decision-making. Conferences such as AACN NTI allow us to further strengthen relationships with healthcare providers and expand awareness across leading hospital systems nationwide.”
Members of the Company’s clinical, commercial, and management teams will be onsite throughout the AACN NTI conference to conduct product demonstrations, engage with healthcare professionals, and discuss the evolving role of bedside enteral navigation technologies in modern hospital care.
About ENvue Medical, Inc.
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:
- ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
- ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
- Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to, statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com
Media Contact:
KCSA Strategic Communications
Michaela Fawcett, Senior Account Director
PH: (978) 995-4683
envue@kcsa.com
